The gene therapy Zolgensma, developed and marketed by the pharmaceutical company Novartis, won both FDA approval and the title of "world's most expensive drug" earlier this year. It's recently come to light, however, that Novartis knowingly provided the FDA with manipulated data during the drug approval process. Dr. Chris Gerry explains what went wrong, why this is such a big deal, and whether Zolgensma should stay on the market.
Harvard's Chris Gerry, Ph.D. has previously written about Zolgensma, the world's most expensive drug, and some of the economics behinds its price. Is Zolgensma, the only treatment for spinal muscular atrophy, too expensive, a bargain, or somewhere in between? As Oscar Wilde once said, “the truth is rarely pure and never simple.”